Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (161-170 of 220) with videos related to

Pageof 22
Sort By:
The Journal of Infectious Diseases|August 4, 2007
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patientsPablo Labarga, Vicente Soriano, Maria Eugenia Vispo, et al.
The Journal of Infection|April 2, 2013
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid responseKarin Neukam, Pablo Barreiro, Antonio Rivero-Juárez, et al.
HIV Clinical Trials|October 27, 2010
Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trialEugenia Vispo, Pablo Barreiro, Ivana Maida, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirinKarin Neukam, Pablo Barreiro, Juan Macías, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patientsAna Lucía Rendón, Marina Núñez, Miriam Romero, et al.
Antiviral Therapy|September 14, 2010
Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapyPaula Tuma, Jose Medrano, Salvador Resino, et al.
AIDS Research and Human Retroviruses|September 23, 2006
Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patientsMaría José Núñez, Luz Martín-Carbonero, Victoria Moreno, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovirTeresa García-Benayas, Ana Lucía Rendón, Sonia Rodríguez-Novóa, et al.
HIV Clinical Trials|August 21, 2002
Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug familiesCarmen de Mendoza, Luz Martín-Carbonero, Pablo Barreiro, et al.
AIDS Research and Human Retroviruses|May 30, 2008
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoringSonia Rodríguez-Nóvoa, Judit Morello, Pablo Barreiro, et al.
Pageof 22

Showing results (161-170 of 220) with videos related to

Sort By:
Pageof 22
The Journal of Infectious Diseases|August 4, 2007
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patientsPablo Labarga, Vicente Soriano, Maria Eugenia Vispo, et al.
The Journal of Infection|April 2, 2013
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid responseKarin Neukam, Pablo Barreiro, Antonio Rivero-Juárez, et al.
HIV Clinical Trials|October 27, 2010
Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trialEugenia Vispo, Pablo Barreiro, Ivana Maida, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirinKarin Neukam, Pablo Barreiro, Juan Macías, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patientsAna Lucía Rendón, Marina Núñez, Miriam Romero, et al.
Antiviral Therapy|September 14, 2010
Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapyPaula Tuma, Jose Medrano, Salvador Resino, et al.
AIDS Research and Human Retroviruses|September 23, 2006
Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patientsMaría José Núñez, Luz Martín-Carbonero, Victoria Moreno, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovirTeresa García-Benayas, Ana Lucía Rendón, Sonia Rodríguez-Novóa, et al.
HIV Clinical Trials|August 21, 2002
Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug familiesCarmen de Mendoza, Luz Martín-Carbonero, Pablo Barreiro, et al.
AIDS Research and Human Retroviruses|May 30, 2008
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoringSonia Rodríguez-Nóvoa, Judit Morello, Pablo Barreiro, et al.
Pageof 22